San Jose, California (openPR) 24 June 2009

Lung cancer is one of the most common cancers worldwide, which not only increases the mortality rates but also improving the financial burden on society. The worldwide market for therapies against cancer of the lung is driven by factors such as line extensions for existing products, introduction of innovative products and advances in biotechnology. Cytotoxic drugs such as cisplatin, carboplatin, docetaxel (Taxotere), paclitaxel and gemcitabine (Gemzar ®) continues to dominate the pharmaceutical market for lung cancer, although targeted therapies have begun to impact the market. The lack of data demonstrating the clinical efficacy of targeted drugs contributes to the further use of cytotoxic drugs for the treatment of lung cancer.

Tarceva should continue its dominance in the global market for treatments for lung cancer, while approvals for Avastin, Erbitux, Zactima and other new therapies are expected to offer growth opportunities. Although the patents of the three major chemotherapy drugs – Paraplatin (carboplatin) to expire, Taxotere (docetaxel) and Gemzar (gemcitabine) in 2012, the development of new drugs and therapies is expected to offset declining revenues.

United States and Europe together dominate the world of non-small cell lung cancer therapeutics market, as identified in the report of the search for new markets. The market for therapies for small cell lung cancer in the U.S. due to the introduction of new immune therapies and increased uptake of VEGF (vascular endothelial growth factor) inhibitors such as Avastin. In addition, the introduction of targeted drugs such as Erbitux and Zactima expected the market sales of non-small cell lung cancer therapy. The introduction of Pfizer ProMune for pre Stimuvax NSCLC and Merck Serono for stage III NSCLC is expected that the growth prospects improve in the short term.


Key players in

lung cancer overall market for therapies include AstraZeneca Plc, Bristol-Myers Squibb, Eli Lilly & Co., F. Hoffmann-La Roche AG, Genentech Inc., GlaxoSmithKline plc, Novartis Pharmaceuticals Corporation, OSI Pharmaceuticals Inc. . and Sanofi-Aventis, among others.

report, “Lung Cancer Therapeutics: A Global Strategic Business Report, entitled” announced by Global Industry Analysts, Inc., presented an overview of market trends, product introductions / innovations, and recent activities of the industry. The report analyzes market data and analysis for non-small cell lung cancer Therapeutics in the following regions – USA, Europe and the world.

For more details on this report on the study of the market, please visit –

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a renowned publisher of off-market research in the trade. Founded in 1987, the company is recognized worldwide as one of the world’s largest market research publishers recognized. The company employs over 800 people worldwide and publishes more than 1,100 large-scale research reports each year. In addition, the company also offers thousands of research products including reports of small businesses, reports on market trends and industry reports include all major industries worldwide.


Industry analysts

Global, Inc.

Tel 408-528-9966

Fax 408-528-9977

email press (at) StrategyR (dot) com
>
Http://www.StrategyR.com/ website

P

###

clear = “all”
small cell lung cancer